Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association

ACS Chem Neurosci. 2023 Nov 1;14(21):3883-3893. doi: 10.1021/acschemneuro.3c00418. Epub 2023 Oct 12.

Abstract

In recent years, the role of new factors in the pathophysiology of neurodegenerative diseases has been investigated. Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide. Although pathological changes such as the accumulation of aggregated proteins in the brain and inflammatory responses are known as the main factors involved in the development of these diseases, new studies show the role of gut microbiota and circadian rhythm in the occurrence of these changes. However, the association between circadian rhythm and gut microbiota in AD and PD has not yet been investigated. Recent results propose that alterations in circadian rhythm regulators, mainly Bmal1, may regulate the abundance of gut microbiota. This correlation has been linked to the regulation of the expression of immune-related genes and Bmal-1 mediated oscillation of IgA and hydrogen peroxide production. These data seem to provide new insight into the molecular mechanism of melatonin inhibiting the progression of AD and PD. Therefore, this manuscript aims to review the role of the gut microbiota and circadian rhythm in health and AD and PD and also presents a hypothesis on the effect of melatonin on their communication.

Keywords: Alzheimer’s disease; Bmal1; Parkinson’s disease; gut microbiota; melatonin.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Melatonin* / metabolism
  • Neurodegenerative Diseases*
  • Parkinson Disease* / drug therapy

Substances

  • Melatonin